TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

SCIRENT CLINICAL RESEARCH AND SCIENCE

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

SCIRENT CLINICAL RESEARCH AND SCIENCE

ST13

US500000079320671

Classe

42

Pedido

79320671

Registro

6868383

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

25

Atualização mais recente

21/03/2023

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

42

Data de depósito

21/04/2021

Data de registro

11/10/2022

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

11/10/2022

Última transação

11/10/2022

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

3

Tipo de titular

99

Localização do titular

RS

Examinador

BLANE, SUZANNE

Unidade examinadora

M50

Localização atual

PUBLICATION AND ISSUE SECTION

Descrição da marca

The sign consists of the word SCIRENT, in Latin capital letters, in black. Below the word SCIRENT, there are four words - Clinical Research and Science, in Latin letters, in blue. In the upper right corner, above the word SCIRENT there is a circle in different shades of green and blue (light green, dark green, light blue, dark blue) whose center is painted in white

Titulares e representantes

Titulares

SCIRENT CLINICAL RESEARCH AND SCIENCE D.O.O. BEOGRAD-VRACAR

Representantes

Clemens W. Pauly Pauly P.A.

Classificação técnica

Classes Nice

Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 42

Medical and scientific research and data analysis services; implementation and analysis of clinical trials in the field of medicines, medical devices, biotechnology and natural sciences; development of protocols, scientific consultation, and preparation of reports with respect to medical research; research center project management; local and global clinical trial project management; pharmaceutical drug development services, development of clinical trial methodologies; consultancy services in the field of pharmaceutical clinical trials; extensive clinical research services for others; electronic storage services for clinical trial data; biostatic analysis; services provided by consultants with respect to research in the field of environmental protection, preclinical research and evaluation of pharmaceutical product development; conducting clinical trials for others in the nature of scientific research, especially the correction of clinical trials and defective records; clinical trial services in the nature of strategic management of clinical research portfolios and follow-up of biological monitoring; providing information in the field of natural sciences and scientific research to physicians and other health professionals, to patients and to medical, pharmaceutical and biotechnological companies; providing technical drafting services for complaints and/or disputes in the field of medical research and clinical studies; consultation services in the field of clinical research under contract and product development under contact; design and development of computer hardware as well as consultation services relating thereto for others; creating websites featuring blogs on medical and pharmaceutical information relating to chronic conditions and diseases; creating and maintaining Internet websites for patients and registered care providers to form virtual communities and to engage in the field of health; design and development of an interactive software for use in the communication and dissemination of medical and pharmaceutical information

Publicações

Histórico de despachos e eventos da marca no USPTO.

25 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

21/03/2023

XXSS

GENERIC MADRID TRANSACTION SENT TO IB

30/01/2023

XXCR

GENERIC MADRID TRANSACTION CREATED

30/01/2023

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

11/01/2023

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

11/10/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

11/10/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

26/07/2022

PUBO

PUBLISHED FOR OPPOSITION

26/07/2022

GPNX

NOTIFICATION PROCESSED BY IB

25/07/2022

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

07/07/2022

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

06/07/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/07/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

22/06/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/06/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/06/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/06/2022

RFNT

REFUSAL PROCESSED BY IB

06/02/2022

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

18/01/2022

RFRR

REFUSAL PROCESSED BY MPU

18/01/2022

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

23/12/2021

CNRT

NON-FINAL ACTION WRITTEN

22/12/2021

DOCK

ASSIGNED TO EXAMINER

15/12/2021

MAFR

APPLICATION FILING RECEIPT MAILED

01/10/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

27/09/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

16/09/2021

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace SCIRENT CLINICAL RESEARCH AND SCIENCE ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.